Trends in enzyme therapy for phenylketonuria

Woomi Kim, Heidi Erlandsen, Sankar Surendran, Raymond C. Stevens, Alejandra Gamez, Kimberlee Michols-Matalon, Stephen K. Tyring, Reuben Matalon

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by phenylalanine hydroxylase (PAH) deficiency. Dietary treatment has been the cornerstone for controlling systemic phenylalanine (Phe) levels in PKU for the past 4 decades. Over the years, it has become clear that blood Phe concentration needs to be controlled for the life of the patient, a difficult task taking into consideration that the diet becomes very difficult to maintain. Therefore alternative models of therapy are being pursued. This review describes the progress made in enzyme replacement therapy for PKU. Two modalities are discussed, PAH and phenylalanine ammonia-lyase PAH. Developing stable and functional forms of both enzymes has proven difficult, but recent success in producing polyethylene glycol-modified forms of active and stable PAH shows promise.

Original languageEnglish (US)
Pages (from-to)220-224
Number of pages5
JournalMolecular Therapy
Volume10
Issue number2
DOIs
StatePublished - Aug 2004

Fingerprint

Enzyme Therapy
Phenylketonurias
Phenylalanine Hydroxylase
Phenylalanine
Inborn Errors Amino Acid Metabolism
Phenylalanine Ammonia-Lyase
Enzyme Replacement Therapy
Complementary Therapies
Diet
Enzymes

Keywords

  • Enzyme replacement therapy
  • Microencapsulation
  • PEGylation
  • Phenylalanine ammonia-lyase
  • Phenylalanine hydroxylase
  • Phenylketonuria

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Kim, W., Erlandsen, H., Surendran, S., Stevens, R. C., Gamez, A., Michols-Matalon, K., ... Matalon, R. (2004). Trends in enzyme therapy for phenylketonuria. Molecular Therapy, 10(2), 220-224. https://doi.org/10.1016/j.ymthe.2004.05.001

Trends in enzyme therapy for phenylketonuria. / Kim, Woomi; Erlandsen, Heidi; Surendran, Sankar; Stevens, Raymond C.; Gamez, Alejandra; Michols-Matalon, Kimberlee; Tyring, Stephen K.; Matalon, Reuben.

In: Molecular Therapy, Vol. 10, No. 2, 08.2004, p. 220-224.

Research output: Contribution to journalArticle

Kim, W, Erlandsen, H, Surendran, S, Stevens, RC, Gamez, A, Michols-Matalon, K, Tyring, SK & Matalon, R 2004, 'Trends in enzyme therapy for phenylketonuria', Molecular Therapy, vol. 10, no. 2, pp. 220-224. https://doi.org/10.1016/j.ymthe.2004.05.001
Kim W, Erlandsen H, Surendran S, Stevens RC, Gamez A, Michols-Matalon K et al. Trends in enzyme therapy for phenylketonuria. Molecular Therapy. 2004 Aug;10(2):220-224. https://doi.org/10.1016/j.ymthe.2004.05.001
Kim, Woomi ; Erlandsen, Heidi ; Surendran, Sankar ; Stevens, Raymond C. ; Gamez, Alejandra ; Michols-Matalon, Kimberlee ; Tyring, Stephen K. ; Matalon, Reuben. / Trends in enzyme therapy for phenylketonuria. In: Molecular Therapy. 2004 ; Vol. 10, No. 2. pp. 220-224.
@article{cb27edd9689d408b86b4513cc25c613c,
title = "Trends in enzyme therapy for phenylketonuria",
abstract = "Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by phenylalanine hydroxylase (PAH) deficiency. Dietary treatment has been the cornerstone for controlling systemic phenylalanine (Phe) levels in PKU for the past 4 decades. Over the years, it has become clear that blood Phe concentration needs to be controlled for the life of the patient, a difficult task taking into consideration that the diet becomes very difficult to maintain. Therefore alternative models of therapy are being pursued. This review describes the progress made in enzyme replacement therapy for PKU. Two modalities are discussed, PAH and phenylalanine ammonia-lyase PAH. Developing stable and functional forms of both enzymes has proven difficult, but recent success in producing polyethylene glycol-modified forms of active and stable PAH shows promise.",
keywords = "Enzyme replacement therapy, Microencapsulation, PEGylation, Phenylalanine ammonia-lyase, Phenylalanine hydroxylase, Phenylketonuria",
author = "Woomi Kim and Heidi Erlandsen and Sankar Surendran and Stevens, {Raymond C.} and Alejandra Gamez and Kimberlee Michols-Matalon and Tyring, {Stephen K.} and Reuben Matalon",
year = "2004",
month = "8",
doi = "10.1016/j.ymthe.2004.05.001",
language = "English (US)",
volume = "10",
pages = "220--224",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Trends in enzyme therapy for phenylketonuria

AU - Kim, Woomi

AU - Erlandsen, Heidi

AU - Surendran, Sankar

AU - Stevens, Raymond C.

AU - Gamez, Alejandra

AU - Michols-Matalon, Kimberlee

AU - Tyring, Stephen K.

AU - Matalon, Reuben

PY - 2004/8

Y1 - 2004/8

N2 - Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by phenylalanine hydroxylase (PAH) deficiency. Dietary treatment has been the cornerstone for controlling systemic phenylalanine (Phe) levels in PKU for the past 4 decades. Over the years, it has become clear that blood Phe concentration needs to be controlled for the life of the patient, a difficult task taking into consideration that the diet becomes very difficult to maintain. Therefore alternative models of therapy are being pursued. This review describes the progress made in enzyme replacement therapy for PKU. Two modalities are discussed, PAH and phenylalanine ammonia-lyase PAH. Developing stable and functional forms of both enzymes has proven difficult, but recent success in producing polyethylene glycol-modified forms of active and stable PAH shows promise.

AB - Phenylketonuria (PKU) is an inborn error of amino acid metabolism caused by phenylalanine hydroxylase (PAH) deficiency. Dietary treatment has been the cornerstone for controlling systemic phenylalanine (Phe) levels in PKU for the past 4 decades. Over the years, it has become clear that blood Phe concentration needs to be controlled for the life of the patient, a difficult task taking into consideration that the diet becomes very difficult to maintain. Therefore alternative models of therapy are being pursued. This review describes the progress made in enzyme replacement therapy for PKU. Two modalities are discussed, PAH and phenylalanine ammonia-lyase PAH. Developing stable and functional forms of both enzymes has proven difficult, but recent success in producing polyethylene glycol-modified forms of active and stable PAH shows promise.

KW - Enzyme replacement therapy

KW - Microencapsulation

KW - PEGylation

KW - Phenylalanine ammonia-lyase

KW - Phenylalanine hydroxylase

KW - Phenylketonuria

UR - http://www.scopus.com/inward/record.url?scp=4344715044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344715044&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.05.001

DO - 10.1016/j.ymthe.2004.05.001

M3 - Article

C2 - 15294168

AN - SCOPUS:4344715044

VL - 10

SP - 220

EP - 224

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -